Syneos Health (SYENS) | Financial Analysis & Statements
Syneos Health, Inc. | Large-cap | Basic Materials
Syneos Health, Inc. | Large-cap | Basic Materials
Financial Overview
Latest Annual: 2024Income Metrics
Revenue
6.8B
Gross Profit
2.2B
32.41%
Operating Income
738.0M
10.78%
Net Income
-5.0M
-0.07%
EPS (Diluted)
-€0.05
Balance Sheet Metrics
Total Assets
12.4B
Total Liabilities
4.9B
Shareholders Equity
7.5B
Debt to Equity
0.65
Cash Flow Metrics
Operating Cash Flow
-46.0M
Free Cash Flow
217.0M
Revenue & Profitability Trend
Syneos Health Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 6.8B | 7.1B | 8.1B | 6.0B | 5.4B |
| Cost of Goods Sold | 4.6B | 4.7B | 5.5B | 4.1B | 3.8B |
| Gross Profit | 2.2B | 2.4B | 2.6B | 1.9B | 1.6B |
| Operating Expenses | 1.5B | 1.2B | 1.4B | 1.0B | 1.2B |
| Operating Income | 738.0M | 1.1B | 1.3B | 746.0M | 462.0M |
| Pre-tax Income | 352.0M | 389.0M | 966.0M | 474.0M | -1.1B |
| Income Tax | 357.0M | 192.0M | 2.0M | 22.0M | 165.0M |
| Net Income | -5.0M | 197.0M | 964.0M | 453.0M | -1.3B |
| EPS (Diluted) | -€0.05 | €1.82 | €8.97 | €4.19 | -€12.14 |
Income Statement Trend
Syneos Health Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | 3.3B | 3.8B | 4.7B | 4.0B | 3.3B |
| Non-Current Assets | 9.1B | 9.1B | 8.9B | 8.7B | 8.1B |
| Total Assets | 12.4B | 12.9B | 13.6B | 12.7B | 11.4B |
| Liabilities | |||||
| Current Liabilities | 1.9B | 1.8B | 5.7B | 5.1B | 4.8B |
| Non-Current Liabilities | 3.0B | 3.4B | 2.9B | 3.2B | 3.5B |
| Total Liabilities | 4.9B | 5.3B | 8.7B | 8.3B | 8.3B |
| Equity | |||||
| Total Shareholders Equity | 7.5B | 7.6B | 4.9B | 4.3B | 3.1B |
Balance Sheet Composition
Syneos Health Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -5.0M | 197.0M | 964.0M | 453.0M | -1.3B |
| Operating Cash Flow | -46.0M | 484.0M | 755.0M | 65.0M | -845.0M |
| Investing Activities | |||||
| Capital Expenditures | -500.0M | -761.0M | -515.0M | -330.0M | -233.0M |
| Investing Cash Flow | -494.0M | -1.3B | -679.0M | -488.0M | -280.0M |
| Financing Activities | |||||
| Dividends Paid | -170.0M | -436.0M | -237.0M | -271.0M | -338.0M |
| Financing Cash Flow | -449.0M | 1.1B | -420.0M | 19.0M | -484.0M |
| Free Cash Flow | 217.0M | 425.0M | 745.0M | 274.0M | 775.0M |
Cash Flow Trend
Syneos Health Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
377.86
Forward P/E
9.06
Price to Book
1.03
Price to Sales
1.01
PEG Ratio
9.06
Profitability Ratios
Profit Margin
-1.59%
Operating Margin
8.76%
Return on Equity
-1.38%
Return on Assets
3.27%
Financial Health
Current Ratio
1.58
Debt to Equity
28.51
Per Share Data
EPS (TTM)
-€1.03
Book Value per Share
€65.17
Revenue per Share
€65.26
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| syens | 6.9B | 377.86 | 1.03 | -1.38% | -1.59% | 28.51 |
| Solvay SA | 3.1B | 15.83 | 2.26 | 14.16% | 3.88% | 155.68 |
| Basilix Cert | 3.7M | - | - | 695.33% | 0.00% | 25.22 |
| Anheuser-Busch InBev | 120.4B | 21.06 | 1.57 | 6.60% | 11.75% | 81.53 |
| Azelis Group NV | 3.2B | 17.86 | 1.12 | 6.77% | 4.29% | 63.15 |
| Titan Cement | 2.9B | 9.97 | 1.41 | 15.09% | 10.55% | 33.45 |
Financial data is updated regularly. All figures are in the company's reporting currency.